Medical Monitoring and Crisis Intervention

Cluster covering 35 related competencies for monitoring acute psychological effects, recognising and managing distress, crisis containment, emergency escalation, and rescue-medication coordination during psychedelic dosing sessions.

8 care stages · 51 guidelines · 2 courses · 2 providers

Teaches ongoing participant contact after dosing to support stability, detect delayed adverse effects, maintain therapeutic containment, and sustain adherence to follow-up visits and outcome assessments.

7 care stages · 37 guidelines · 0 courses · 0 providers

Teaches how to determine when a participant is safe to leave after dosing and how to arrange appropriate supervision afterward. The competency covers psychological and physical stability, escort/support-person coordination, discharge restrictions, overnight or post-session support, and follow-up contact when needed.

8 care stages · 30 guidelines · 0 courses · 0 providers

Teaches recognition of medical or psychiatric emergencies and the steps required to escalate care safely. The competency includes de-escalation, clinical consultation, 911 or emergency department transfer, serious-event escalation, and referral to appropriate higher-level care.

7 care stages · 29 guidelines · 3 courses · 3 providers

Cluster covering 3 related competencies including: Physical safety monitoring, Safety monitoring during dosing sessions, Medical safety monitoring during psilocybin administration.

6 care stages · 19 guidelines · 0 courses · 0 providers

Teaches continuous monitoring for distress, confusion, psychotic symptoms, suicidality, agitation, and other acute behavioral risks during and after dosing. The focus is early recognition, documentation, and escalation to clinical support when risk emerges.

7 care stages · 17 guidelines · 0 courses · 0 providers

Teaches recognition and management of expected and unexpected side effects during psychedelic or ketamine treatment. The competency emphasizes active observation, supportive response, and clinical escalation when symptoms exceed routine tolerability.

6 care stages · 14 guidelines · 1 courses · 1 providers

Teaches recognition and documentation of dissociation, psychosis-like symptoms, mania, and other acute neuropsychiatric effects that can occur after ketamine, psychedelic dosing, or related interventions. The focus is monitoring, reporting, and escalation when symptoms become clinically significant.

7 care stages · 12 guidelines · 0 courses · 0 providers

Teaches monitoring and response for acute physiological risks, including vital signs, temperature, hydration, overheating, excessive fluid intake, and suspected overdose. The competency emphasizes supportive care, medical coordination, documentation, and escalation when needed.

5 care stages · 11 guidelines · 0 courses · 0 providers

The protocol requires active monitoring for psychedelic-specific adverse events such as hallucinations, psychotic symptoms, dissociation, mood alteration, and cognitive disturbance. These require immediate notification and follow-up.

7 care stages · 11 guidelines · 0 courses · 0 providers

Teaches how clinicians determine whether a participant should proceed, pause, discontinue dosing, or terminate study participation. The competency centers on safety-driven clinical judgment, risk-benefit assessment, and early termination when continuation is no longer appropriate.

6 care stages · 8 guidelines · 0 courses · 0 providers

Cluster covering 2 related competencies including: Safety monitoring during ketamine dosing, Physiologic monitoring during ketamine administration.

6 care stages · 8 guidelines · 0 courses · 0 providers

Monitors participant physical status during study visits and identifies concerning changes requiring escalation. Vital signs and symptomatic changes are part of routine safety observation.

6 care stages · 8 guidelines · 0 courses · 0 providers

Cluster covering 2 related competencies including: Medical escalation and rescue medication use, Medical escalation and rescue medication coordination.

4 care stages · 7 guidelines · 0 courses · 0 providers

Cluster covering 5 related competencies including: Cardiac safety monitoring, Ketamine infusion monitoring, Ketamine infusion administration.

6 care stages · 6 guidelines · 0 courses · 0 providers

Teaches counseling and monitoring around contraception, reproductive restrictions, pregnancy risk, and pregnancy-related discontinuation rules. Learners are trained to explain requirements clearly and respond promptly when pregnancy or reproductive-safety concerns arise.

5 care stages · 6 guidelines · 0 courses · 0 providers

Therapists must ensure continuity of care after the acute session, including overnight observation and next-morning integration before discharge. This reflects a containment and recovery responsibility beyond the dosing period.

5 care stages · 5 guidelines · 0 courses · 0 providers

Teaches continuous evaluation of clinical risk and maintenance of a safe care environment throughout preparation, dosing, and follow-up. Learners monitor risk signals, apply safety procedures, and escalate care when needed.

8 care stages · 4 guidelines · 3 courses · 2 providers

Respond to agitation or attempts to leave the room in a way that preserves safety for the patient and others. The therapist should use containment, redirection, and escalation protocols when needed.

4 care stages · 4 guidelines · 0 courses · 0 providers

Therapists must prepare the subject for residual effects after the main session and provide practical safeguards for sleep, transportation, and home support. This includes framing recurrence of symptoms in a non-alarming way.

3 care stages · 4 guidelines · 0 courses · 0 providers

Study clinicians are responsible for administering study drug, ensuring correct dose assignment, and supervising safe oral ingestion during blinded sessions. This includes verifying visit-specific randomization information and ensuring dosing is delivered under the blinded workflow.

3 care stages · 4 guidelines · 0 courses · 0 providers

The study emphasizes the absence of acute or chronic adverse effects persisting beyond 1 day and no treatment-related serious adverse events, indicating the need for active monitoring during and after treatment. Facilitators must be able to observe, document, and respond to adverse reactions.

5 care stages · 4 guidelines · 0 courses · 0 providers

The page signals training in managing difficult or high-risk moments, including crisis intervention and trigger management. Learners are expected to respond appropriately when a session becomes destabilizing or unsafe.

6 care stages · 3 guidelines · 1 courses · 1 providers

The page points to checklists and a guide to basic medical emergencies, indicating that learners should be able to monitor safety and recognize urgent issues. The overall training context also stresses keeping both client and practitioner safe.

6 care stages · 3 guidelines · 1 courses · 1 providers

Monitor for ibogaine-associated cardiac toxicity, especially QTc prolongation and risk of torsades de pointes. This includes baseline exclusion screening, frequent ECG surveillance, and escalation when QTc becomes markedly prolonged.

3 care stages · 3 guidelines · 0 courses · 0 providers

Reviews laboratory and ECG data for clinically relevant abnormalities and determines whether continued participation is appropriate. Escalates abnormalities requiring repeat testing or specialist input.

2 care stages · 3 guidelines · 0 courses · 0 providers

Monitor and respond to the expected sympathomimetic effects of MDMA. The therapist/facilitator must be alert to transient increases in blood pressure, pulse, and related cardiac symptoms.

3 care stages · 3 guidelines · 0 courses · 0 providers

Because the protocol involved specific LSD doses, active placebo control, and session spacing, facilitators need applied skill in implementing dosing-session procedures safely and consistently. This includes maintaining therapeutic support while adhering to protocol constraints.

4 care stages · 3 guidelines · 0 courses · 0 providers

Learners are explicitly offered Basic Life Support training, indicating emergency readiness and medical safety preparation. The page notes DORA-required status, signaling regulatory safety relevance.

4 care stages · 2 guidelines · 1 courses · 1 providers

Therapists must remain with participants at the end of and immediately after experimental sessions until emotional stability is established. This requires real-time clinical judgment about readiness for reduced supervision.

3 care stages · 2 guidelines · 0 courses · 0 providers

Ability to monitor for short-term cognitive impairment following psychedelic administration. The study included tests designed to detect decrements in attention and processing speed.

3 care stages · 2 guidelines · 0 courses · 0 providers

Review laboratory and biomarker data for clinically significant abnormalities, including chemistry, hematology, coagulation, and alcohol biomarkers. This supports medical safety surveillance during follow-up.

3 care stages · 2 guidelines · 0 courses · 0 providers

Safety monitoring in this context includes tracking not only adverse psychiatric states but also broader psychological, emotional, existential, and spiritual outcomes. Clinicians should watch for changes across multiple domains that may affect patient functioning and care needs.

3 care stages · 2 guidelines · 0 courses · 0 providers

Performs targeted nasal examinations and assesses local tolerability of esketamine nasal spray. Identifies findings that could affect drug delivery, safety, or continuation.

3 care stages · 2 guidelines · 0 courses · 0 providers

Monitors patients closely during treatment because serious adverse outcomes may occur. Safety monitoring is essential given that one participant died during treatment in the study.

3 care stages · 2 guidelines · 0 courses · 0 providers

Facilitators must watch for slowed breathing, sleep apnea-related hypoxia, disordered breathing, and oxygen desaturation. Oxygenation needs ongoing assessment during the acute and post-acute periods.

4 care stages · 2 guidelines · 0 courses · 0 providers

Monitors for potential adverse effects associated with ibogaine administration and the detoxification period, even though the abstract primarily reports outcomes rather than specific events.

3 care stages · 2 guidelines · 0 courses · 0 providers

Measure opioid withdrawal severity using standardized instruments and interpret symptom severity over time. Facilitators must be able to collect both objective observation and patient-reported data.

4 care stages · 2 guidelines · 0 courses · 0 providers

Track the participant’s subjective drug intensity during the active phase of the session. This includes recognizing when the participant cannot respond and how to document maximum intensity.

3 care stages · 1 guidelines · 0 courses · 0 providers

Assess for cerebellar adverse effects such as ataxia during and after ibogaine administration. The source indicates ataxia is likely driven by ibogaine exposure and should be tracked systematically.

3 care stages · 1 guidelines · 0 courses · 0 providers

Understands and monitors concentration-related cardiac risk, especially QTc prolongation, in participants receiving noribogaine or similar agents. Uses ECG findings to support safe trial conduct and participant protection.

1 care stage · 1 guidelines · 0 courses · 0 providers

The study specifically reports no QT prolongation, indicating that cardiac safety was an important monitoring domain. Facilitators must be aware of relevant safety surveillance and the need to identify concerning effects.

1 care stage · 1 guidelines · 0 courses · 0 providers

Assess whether an event is related to treatment and resolve uncertainty through team discussion and regulatory escalation. The protocol uses a structured causality framework from unrelated to definitely related.

1 care stage · 1 guidelines · 0 courses · 0 providers

At least one therapist in the dyad must be a clinician with capability to assess and manage medical or psychiatric adverse events during the dosing session. This reflects a required competency boundary between general support and clinical responsibility.

3 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators should know when and how to ask for help and delegate tasks. This is essential in emergencies and difficult situations.

1 care stage · 1 guidelines · 0 courses · 0 providers

Ability to judge clinical worsening over time and determine whether a participant can remain in the study or requires higher-level care. This is a continuing monitoring responsibility throughout the trial.

1 care stage · 1 guidelines · 0 courses · 0 providers

Be prepared to recognize medical deterioration and summon emergency help immediately. The manual states that providers who cannot call for emergency assistance should not provide ibogaine therapy.

2 care stages · 1 guidelines · 0 courses · 0 providers

Therapists/facilitators should be able to educate companions about clinical warning signs and how to contact the study team. This extends monitoring beyond the clinic and supports rapid response to deterioration.

1 care stage · 1 guidelines · 0 courses · 0 providers

Responds appropriately to safety threats disclosed in group therapy. Follows up on suicide, homicide, abuse, or neglect concerns and escalates when necessary.

1 care stage · 1 guidelines · 0 courses · 0 providers

Prevent dehydration during and after ibogaine treatment. The manual stresses that patients may not feel like drinking and that dehydration can become dangerous, especially if vomiting occurs.

3 care stages · 1 guidelines · 0 courses · 0 providers

Understand the unique cardiovascular hazards associated with ibogaine and the need for intensive cardiac oversight. The facilitator should know that cardiac risk is a central safety issue rather than a minor side effect.

2 care stages · 1 guidelines · 0 courses · 0 providers

Understands the implications of PET, MRI, blood sampling, and TMS-EEG procedures for participant comfort and safety. While not necessarily performing these procedures, the therapist/facilitator should know their risks and scheduling constraints.

2 care stages · 1 guidelines · 0 courses · 0 providers

Understand that classic psychedelics can cause moderate increases in blood pressure, heart rate, temperature, and pupil size without necessarily indicating severe toxicity. Proper interpretation helps avoid overreaction while remaining vigilant.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand that ibogaine has a significant toxicity profile, especially cardiotoxicity. Fatalities have been temporally associated with use, often in the setting of medical comorbidity, co-use, or electrolyte imbalance.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists must provide continuity, availability, and clear support structures after MDMA sessions to reduce anxiety and manage emerging difficulties. This safety net extends beyond the dosing day.

5 care stages · 1 guidelines · 0 courses · 0 providers

Providers must be able to recognize and safely manage acute confusional states, which may look like a psychological break from reality. The emphasis is on physical safety, constant supervision, and avoiding abrupt antipsychotic intervention.

2 care stages · 1 guidelines · 0 courses · 0 providers

Therapists in this setting must recognize abnormal cardiovascular responses and follow protocolized responses for hypertensive crisis, angina, myocardial infarction, or stroke.

2 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators must be able to contain and support intense psychological distress during the session. The study notes that the experience could be emotionally difficult even when participants felt safe.

1 care stage · 1 guidelines · 0 courses · 0 providers

Respond promptly to complications arising during ibogaine-supported detoxification. Facilitators need a clear escalation plan for QTc prolongation and intolerable withdrawal.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists/facilitators must monitor for adverse medical signs during sessions and obtain targeted testing when clinically indicated. Safety practice should balance participant comfort with symptom-triggered medical evaluation.

2 care stages · 1 guidelines · 0 courses · 0 providers

Monitor for cerebellar toxicity and gait disturbance because severe transient ataxia was observed in all patients in the study. The facilitator must be able to detect impaired coordination and prevent falls or injury.

2 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators must protect participants and others from harm without unnecessarily restraining the participant. The guidance emphasizes containing danger rather than restraining movement.

1 care stage · 1 guidelines · 0 courses · 0 providers

A study physician with psychiatric and cardiovascular emergency expertise must be available during dosing. This reflects a requirement for advanced emergency readiness and clinical judgment.

3 care stages · 1 guidelines · 0 courses · 0 providers

Follows the study's operational rules for dose timing, progression, and stopping conditions. Reliable execution is necessary for both safety and interpretability of results.

3 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators must know the risks and contraindications associated with ayahuasca use. They should identify medical and psychological factors that make participation unsafe or require extra caution.

2 care stages · 1 guidelines · 0 courses · 0 providers

Ability to support supervised at-home ketamine use when clinically appropriate. This implies monitoring and structure even outside the office setting.

2 care stages · 1 guidelines · 0 courses · 0 providers

Understand the expected acute physiological effects of BPL-003 and monitor for clinically meaningful changes. The facilitator should recognize that transient blood pressure and heart rate increases may occur.

3 care stages · 1 guidelines · 0 courses · 0 providers

Monitor and address nicotine withdrawal symptoms and smoking urges across the treatment window. Facilitators help participants manage discomfort and sustain abstinence through high-risk periods.

2 care stages · 1 guidelines · 0 courses · 0 providers

Support patients through acute opioid withdrawal during ibogaine treatment when withdrawal symptoms are present. The source describes use of oral hydromorphone for symptom relief within the protocol.

1 care stage · 1 guidelines · 0 courses · 0 providers

Teaches structured assessment of suicidal ideation, intent, psychiatric deterioration, and related high-risk presentations. Learners are trained to use appropriate tools, safety planning, emergency contacts, clinician access, and escalation pathways when risk is identified.

7 care stages · 41 guidelines · 1 courses · 1 providers

Teaches a trauma-informed stance during psychedelic work, including calm presence, non-verbal reassurance, body-aware support, somatic orientation, and containment through difficult experiences while maintaining safety and boundaries.

6 care stages · 9 guidelines · 2 courses · 2 providers

Ability to perform or supervise detailed psychiatric evaluation for diagnosis, eligibility, and ongoing monitoring. The therapist/facilitator must understand symptom presentations relevant to MDD, AUD, suicidality, psychosis, and dissociation.

4 care stages · 9 guidelines · 0 courses · 0 providers

Therapists must be able to teach and coach grounding practices that help participants regulate during preparation and dosing. These methods are used before medication and during distress.

6 care stages · 9 guidelines · 0 courses · 0 providers

The therapist/facilitator must support structured dose escalation decisions within the individualized dosing regimen. Decisions depend on both patient-reported peak experience and clinical tolerability/safety judgments.

2 care stages · 7 guidelines · 0 courses · 0 providers

Teaches monitoring during down-titration or discontinuation of psychiatric medications before dosing. Learners track withdrawal symptoms, symptom worsening, suicidality, and other risks that may emerge during tapering.

4 care stages · 6 guidelines · 0 courses · 0 providers

Facilitate trauma exposure in a structured, supportive, and protocol-consistent manner. The therapist must be able to initiate, pace, and process exposure work while maintaining adherence to PE methods.

5 care stages · 5 guidelines · 0 courses · 0 providers

The facilitator should know how oral and intravenous dosing relate to onset, duration, and peak effects. This knowledge supports proper session planning, monitoring, and integration timing.

6 care stages · 5 guidelines · 0 courses · 0 providers

Teaches screening for MRI contraindications and coordination of imaging clearance before scan procedures. The competency prevents exposure of ineligible participants to magnetic-resonance risks and supports safe imaging-session logistics.

3 care stages · 3 guidelines · 0 courses · 0 providers

Evaluates opioid withdrawal symptoms and tracks changes over time in participants discontinuing methadone OST. Uses standardized withdrawal ratings to assess potential treatment effects and safety.

4 care stages · 3 guidelines · 0 courses · 0 providers

Understand the major medical risks associated with ibogaine administration, especially cardiac and neurologic toxicity, before proceeding with treatment. This includes recognizing that ibogaine has been linked to torsades de pointes, QTc prolongation, bradycardia, and ataxia.

4 care stages · 3 guidelines · 0 courses · 0 providers

Ability to monitor for opioid use recurrence, other substance use, and ketamine misuse during the trial. The clinician must recognize relapse risk and take action when substance use worsens.

3 care stages · 3 guidelines · 0 courses · 0 providers

Therapists should identify or teach in-session coping tools and collaboratively plan how anxiety states will be recognized and supported.

3 care stages · 3 guidelines · 0 courses · 0 providers

Cluster covering 5 related competencies including: Harm-reduction orientation, Harm reduction and risk awareness, Harm reduction for client support.

8 care stages · 2 guidelines · 5 courses · 5 providers

Therapists function within a medically supervised ketamine model and must coordinate closely with clinicians responsible for dosing oversight and safety clearance. This includes understanding role boundaries and supporting monitoring workflows.

2 care stages · 2 guidelines · 0 courses · 0 providers

Therapists/facilitators must fulfill professional legal duties and escalate safety or reporting concerns promptly.

3 care stages · 2 guidelines · 0 courses · 0 providers

Coordinate the conversion from opioid maintenance treatment to morphine-sulphate prior to ibogaine dosing, reflecting the treatment sequence described in the study. This requires careful timing and clinical oversight.

3 care stages · 2 guidelines · 0 courses · 0 providers

When overnight stays are required, facilitators and attendants must maintain safe observation and supportive presence without acting as outside therapists. They need to monitor comfort, safety, and emergency access overnight.

4 care stages · 2 guidelines · 0 courses · 0 providers

The facilitator must ensure non-responders are transitioned safely back to clinical care. Continuity of care is explicitly required to support ongoing psychiatric treatment.

4 care stages · 2 guidelines · 0 courses · 0 providers

Understands the drug’s rapid absorption profile and lack of accumulation with repeated dosing. Uses this knowledge to anticipate timing of effects and safety observations.

2 care stages · 2 guidelines · 0 courses · 0 providers

Balances potential symptom relief against known and emerging safety risks in participants with opioid dependence. Makes conservative decisions when cardiac or adverse-effect concerns outweigh anticipated benefit.

2 care stages · 2 guidelines · 0 courses · 0 providers

Therapists must have a thorough understanding of MDMA’s subjective, relational, and physiological effects, including the non-linear way these may support healing. This knowledge is necessary for preparation, in-session decisions, and normalization of participant experiences.

4 care stages · 2 guidelines · 0 courses · 0 providers

LSD-assisted psychotherapy in this study is explicitly framed as medically supervised. Therapists/facilitators need to practice within a setting capable of medical oversight and management of prolonged altered states.

2 care stages · 2 guidelines · 0 courses · 0 providers

Ability to correctly deliver the investigational inhaled drug using standardized vaporization procedures and participant instructions. Safe and accurate administration is central to the dosing protocol.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators need basic knowledge of ayahuasca composition, dosing, and interaction risks to support safe administration. The protocol emphasizes dose calculation, substance composition, and monitoring for contraindications.

4 care stages · 1 guidelines · 0 courses · 0 providers

Use supportive anxiolytic or hypnotic medication only when allowed and clinically indicated. This requires careful judgment to balance comfort, safety, and preservation of the session’s integrity.

3 care stages · 1 guidelines · 0 courses · 0 providers

Evaluate whether a person is an appropriate candidate for ibogaine treatment by balancing potential benefit against medical risk. This includes identifying treatment-refractory opioid use disorder and weighing cardiotoxicity and other safety concerns against the harms of untreated substance use disorder.

2 care stages · 1 guidelines · 0 courses · 0 providers

Screen for cardiovascular risk before treatment because ibogaine may prolong the QT interval and has been linked to arrhythmias and deaths. Exclude or carefully manage patients with cardiac disease and other risk factors.

2 care stages · 1 guidelines · 0 courses · 0 providers

Exclude or defer patients whose medical risk is too high, especially those with cardiovascular disease or other major contraindications. This is central to safer administration according to the source.

3 care stages · 1 guidelines · 0 courses · 0 providers

Ketamine-assisted treatment in this protocol is multidisciplinary, so facilitators must work closely with study doctors and nurses. This includes coordinating preparation, understanding monitoring responsibilities, and escalating concerns appropriately.

4 care stages · 1 guidelines · 0 courses · 0 providers

Implement infection-prevention procedures during in-person study and dosing visits. Facilitators must screen participants, use PPE, maintain distancing when feasible, and adapt procedures based on test results or symptoms.

3 care stages · 1 guidelines · 0 courses · 0 providers

Knowledge of anorexia nervosa symptomatology, risk, and clinical instability relevant to screening and treatment monitoring. The study requires awareness of eating-disorder-specific risks and outcomes.

2 care stages · 1 guidelines · 0 courses · 0 providers

Assess for physiologic factors that may increase ibogaine-related harm, especially electrolyte abnormalities. The source identifies electrolyte screening as part of safer administration.

4 care stages · 1 guidelines · 0 courses · 0 providers

Knows the purpose and indications of medications maintained for side effect management or emergency use during KAP. Can explain how these medications relate to specific risks.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand the common and serious adverse effects, interaction risks, and monitoring needs of escitalopram. This includes cardiac, psychiatric, sexual, and withdrawal-related concerns.

2 care stages · 1 guidelines · 0 courses · 0 providers

Ensure that administration occurs within an ethically supervised research or clinical framework with informed oversight and careful risk-benefit consideration. Hallucinogenic agents require especially cautious use in vulnerable psychiatric populations.

2 care stages · 1 guidelines · 0 courses · 0 providers

After each MDMA session, therapists must assess whether continuing treatment is safe and clinically appropriate. The participant’s choice is respected unless safety concerns warrant exclusion.

2 care stages · 1 guidelines · 0 courses · 0 providers

Knows the use of ibogaine as a detoxification agent in medical and nonmedical settings and understands that its mechanism of action is novel and not fully established.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators need competence in working with PTSD when comorbid conditions are present. The source explicitly notes dissociation, depression, alcohol/substance use disorders, and childhood trauma.

1 care stage · 1 guidelines · 0 courses · 0 providers

5-MeO-DMT produces a very short but intense experience, which changes facilitation demands. Facilitators must be prepared for rapid transitions into and out of the altered state.

5 care stages · 1 guidelines · 0 courses · 0 providers

Because study drug delivery uses a vaporization device, staff must be able to recognize, document, and escalate device deficiencies. Device issues may have safety implications even when no patient harm occurs.

2 care stages · 1 guidelines · 0 courses · 0 providers

The therapist should watch for depression after the experience, particularly when insights are not translated into action. Continued support is presented as a way to reduce this risk and restore constructive orientation.

3 care stages · 1 guidelines · 0 courses · 0 providers

Understand the intranasal administration procedure and related local adverse effects. The facilitator must support safe delivery and monitor nasal reactions.

2 care stages · 1 guidelines · 0 courses · 0 providers

Treat consent as a continuing process rather than a one-time event. Patients must understand the treatment and retain the ability to revoke consent, with special procedures during the medication session for safety.

5 care stages · 1 guidelines · 0 courses · 0 providers

During onset, therapists must help the subject stay relaxed, accept changes, and avoid fixation on somatic discomfort or irrelevant ideation. Music and reassurance are highlighted as practical tools for reducing fear and helping the subject welcome altered perception.

1 care stage · 1 guidelines · 0 courses · 0 providers

The therapist must recognize confusion, paranoia, referential thinking, withdrawal, or grandiosity and respond with steady trust, containment, and continued presence. Management skill is particularly important because these reactions may still be workable and may shift with proper handling.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understands the clinical context of switching participants from methadone to morphine before study participation. Appreciates how opioid substitution transitions can affect symptom interpretation and safety monitoring.

1 care stage · 1 guidelines · 0 courses · 0 providers

Applies cautious patient selection when considering ibogaine for opioid detoxification, particularly for individuals with refractory opioid use disorder.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand ibogaine, noribogaine, and noribogaine glucuronide disposition and how exposure relates to clinical effects. This knowledge supports safe interpretation of observed toxicity and response.

1 care stage · 1 guidelines · 0 courses · 0 providers

Conducts a retrospective psychiatric interview to judge minimal clinical improvement on the current antidepressant regimen. Uses multiple information sources and clinical observation to determine whether the participant meets screening requirements.

1 care stage · 1 guidelines · 0 courses · 0 providers

Initiates, uptitrates, and monitors quetiapine XR augmentation in the comparator arm according to age-specific schedules and tolerability. Recognizes the therapeutic minimum and discontinuation triggers.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists must monitor a clinically vulnerable population experiencing recent loss and possible PGD risk. The protocol requires special attention to psychological destabilization, distress, and functional impairment.

2 care stages · 1 guidelines · 0 courses · 0 providers

Maintain physical, emotional, and relational safety as the primary guiding principle throughout IMAP. Therapists continuously monitor risk, reinforce boundaries, and intervene more directly when safety is compromised.

1 care stage · 1 guidelines · 0 courses · 0 providers

Administers repeated sublingual microdoses of 5-MeO-DMT in a controlled clinical trial setting. Must follow the assigned dose schedule and maintain blinding across active and placebo conditions.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists must closely attend to the patient's speech, affect, movement, silence, and bodily signs to understand process and determine appropriate intervention. Fine-grained observation is necessary for both safety and therapeutic timing.

1 care stage · 1 guidelines · 0 courses · 0 providers

The facilitator must understand why bipolar II participants require enhanced monitoring and conservative dosing. The protocol is built around the risk of mood destabilization in this population.

4 care stages · 1 guidelines · 0 courses · 0 providers

The course explicitly includes ethical and relational considerations in crisis response. This suggests learners are trained to act with care, boundaries, and attunement when responding to acute distress.

3 care stages · 0 guidelines · 1 courses · 1 providers

The course is positioned as a preparedness-oriented training with self-directed preparation plus live facilitated learning. Learners are expected to internalize a framework for managing challenging or crisis moments with confidence and care.

2 care stages · 0 guidelines · 1 courses · 1 providers

Catch-all cluster covering 189 general competencies for psychedelic-assisted clinical practice that did not group into a more specific category — including miscellaneous facilitation, monitoring, ethics, safety, regulatory awareness, group support, and program-specific skills not captured by dedicated clusters elsewhere.

8 care stages · 45 guidelines · 27 courses · 18 providers